Discovery of inhibition of burkholderia cenocepacia, pseudomonas aeruginosa and stenotrophomonas maltophilia by the brown rot basidiomycete fungus, postia placenta

Rachael McIlroy, David W. Nelson, B. Cherie Millar, Alan Murphy, Juluri R. Rao, Damian G. Downey, John E. Moore*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Downloads (Pure)

Abstract

Antimicrobial resistance (AMR) has now emerged as a major global public health problem. Certain bacterial pathogens, particularly Gram negative organisms associated with patients with cystic fibrosis (CF), have become resistant to several classes of antibiotics resulting in pan-resistance, which creates a clinical treatment dilemma. This study wished to explore the production of antibacterial extracellular metabolites from plant pathogenic fungi. Fungal Culture Extracts (FCEs) were prepared from 10 fungi (Armillaria gallica, Clitocybe nebularis, Fusarium coeruleum, Fusarium oxysporum, Fusarium poae, Hymenoscyphus fraxineus, Nectria fuckeliana, Phytophthora infestans, Phytophthora ramorum, Postia placenta), which were tested for activity against the CF pathogens, Pseudomonas aeruginosa (PA) (n=8), Burkholderia cenocepacia (n=2) and Stenotrophomonas maltophilia (n=2). In addition, FCE were assessed for their ability to alter antibiotic susceptibility in PA (n=8), with six antipseudomonal antibiotics (ceftazidime, ciprofloxacin, colistin, meropenem, piperacillin/tazobactam, tobramycin). None of the FCEs showed inhibitory activity to the 12 bacterial isolates tested, with the exception of the FCE from Postia placenta, which showed inhibition against all 12 bacteria. An antagonistic interaction was observed, where a statistically significant decrease in mean zone sizes was noted with Armillaria gallica (p=0.03) and Phytophthora infestans (p=0.03) FCEs and their interaction with the fluoroquinolone antibiotic, ciprofloxacin. Given the increase in clinical morbidity and mortality associated with chronic lung infections with Pseudomonas aeruginosa, Burkholderia cenocepacia and Stenotrophomonas maltophilia, coupled with the difficulty in treating such chronic infection due to overwhelming antimicrobial resistance, any novel substance showing inhibition of these organisms merits further investigation as a potential future antimicrobial agent, with potential clinical therapeutic application.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalUlster Medical Journal
Volume90
Issue number3
Publication statusPublished - 11 Sept 2021

Bibliographical note

Funding Information:
The data in this paper is the product of a collaborative alliance on drug discovery between colleagues at Plant Pathology, AgriFood & Biosciences Institute (AFBI), Newforge Lane, the Northern Ireland Public Health Laboratory, Belfast City Hospital, and the School of Medicine, Dentistry and Biomedical Sciences, QUB and wishes to report on a NI project which contributes to developing novel antimicrobials in the fight against AMR.

Publisher Copyright:
© 2021, Ulster Medical Society. All rights reserved.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Discovery of inhibition of burkholderia cenocepacia, pseudomonas aeruginosa and stenotrophomonas maltophilia by the brown rot basidiomycete fungus, postia placenta'. Together they form a unique fingerprint.

Cite this